Engraftment promotion by anti-CD154 monoclonal antibody is abrogated by anti-CD152 monoclonal antibody
| TBI (cGy) . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|
| 200 | Hamster IgG | 0/10 | 0 ± 0 |
| 200 | Anti-CD154 | 8/9 | 67 ± 273-150 |
| 200 | Anti-CD80, anti-CD86 | 0/10 | 0 ± 0 |
| 200 | Anti-CD154, anti-CD80, CD86 | 9/9 | 75 ± 83-150 |
| 200 | Anti-CD154, anti-CD152 | 0/10 | 0 ± 03-151 |
| TBI (cGy) . | mAb . | No. chimeric . | % Donor . |
|---|---|---|---|
| 200 | Hamster IgG | 0/10 | 0 ± 0 |
| 200 | Anti-CD154 | 8/9 | 67 ± 273-150 |
| 200 | Anti-CD80, anti-CD86 | 0/10 | 0 ± 0 |
| 200 | Anti-CD154, anti-CD80, CD86 | 9/9 | 75 ± 83-150 |
| 200 | Anti-CD154, anti-CD152 | 0/10 | 0 ± 03-151 |
B6 mice were irradiated with 200 cGy TBI on day −1 and infused with 40 × 106 BALB/c BM on day 0. Antibodies were administered from day −1 through day 14 after BMT. PBLs were typed for percentage donor-host chimerism at 139 days after BMT. Chimeric is defined as more than 3% donor PBL. Percentage donor is defined as average percentage donor cells of all mice in the group ± 1 SD.
For abbreviations, see Table 1.
P < .001 compared with hamster IgG.
P < .001 compared with anti-CD154 alone.